Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2022

View Archived Issues

Ginisortamab restores gremlin-1-ablated BMP signaling in CRC cell lines

Novel murine model may shed light for future strategies for aggressive glioblastoma

Servier patents new MAT2A inhibitors

Sumitomo Pharma divulges Chk1 inhibitors

Anti-HER2 domain-specific antibody-drug radioconjugates show promise in models of breast cancer

SAGE Therapeutics describes new GABA-A receptor modulators

Merck & Co. identifies new GLCT-1 inhibitors

Tokyo University of Science discloses LXR antagonists

Silo in commercial evaluation license agreement for next-generation liposomes for autoimmune disease

Dual CXCR4/ACKR3 inhibitor in combination with ICT impedes 4T1 tumor growth and metastasis

FDA clears Fusion's IND applications for FPI-2059 and imaging analogue FPI-2058

[89Zr]-Labeled antibody targeting glypican-1 developed as theranostic for pancreatic cancer

First preclinical data on NR2F6 antagonist TES-4207

Molecular signature predicts cancer risk in patients with NAFLD

Voltron initiates preclinical study of vaccine candidate VTX-067 in immune-oncology model

SAN-903 dampens renal fibrosis in mouse model of chronic kidney disease

Evaxion to advance EVX-03 into clinic for NSCLC

Brilacidin inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants in vitro

Soligenix reports 100% protection in NHPs with bivalent vaccine against MARV and SUDV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...